Trials / Unknown
UnknownNCT03917758
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Turin, Italy · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
Detailed description
The pathophysiological explanations of the cardiovascular improvement of patients treated with SGLT2i are not yet known: osmotic diuresis and natriuresis, direct effects of weight reduction, increased in nitric oxide release, oxidative stress reduction, local renin-angiotensin-aldosterone system (RAAS) inhibition are the supposed mechanism. In the Literature the diuretic effect of SGLT2i therapy seems to be even stronger than thiazide or thiazide-like drugs. However, it is not defined the role of SGLT2i on antidiuretic function (RAAS, brain natriuretic peptide-BNP and antidiuretic hormone-ADH). Defining this relation could be important for: * knowing effect of SGLT2i on RAAS (drugs interferences are important particularly during case detection of primary aldosteronism); * discovering antidiuretic response to SGLT2i treatment and interactions between RAAS, BNP and ADH on the volume improvement induced by this new antidiabetic drugs. In addition the aim of the study is to define effect of treatment on blood pressure and body composition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGLT2 inhibitor | Start of the treatment with SGLT2i. |
Timeline
- Start date
- 2018-10-10
- Primary completion
- 2020-07-30
- Completion
- 2020-10-30
- First posted
- 2019-04-17
- Last updated
- 2020-11-03
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03917758. Inclusion in this directory is not an endorsement.